CY1112135T1 - Ανταγωνιστες υποδοχεα il-8 - Google Patents

Ανταγωνιστες υποδοχεα il-8

Info

Publication number
CY1112135T1
CY1112135T1 CY20111100624T CY111100624T CY1112135T1 CY 1112135 T1 CY1112135 T1 CY 1112135T1 CY 20111100624 T CY20111100624 T CY 20111100624T CY 111100624 T CY111100624 T CY 111100624T CY 1112135 T1 CY1112135 T1 CY 1112135T1
Authority
CY
Cyprus
Prior art keywords
competitive
receptors
competitive receptors
chemokine
interleukin
Prior art date
Application number
CY20111100624T
Other languages
English (en)
Inventor
Jakob Busch-Petersen
Michael R Palovich
Katherine L Widdowson
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of CY1112135T1 publication Critical patent/CY1112135T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Αυτή η εφεύρεση σχετίζεται με νέες ενώσεις του Τύπου (I) ως (VII), και με συνθέσεις αυτών, που είναι χρήσιμες για τη θεραπεία καταστάσεων ασθενείας όπου μεσολαβεί η χημειοκίνη, Ιντερλευκίνη-8 (IL-8).
CY20111100624T 2002-10-29 2011-06-29 Ανταγωνιστες υποδοχεα il-8 CY1112135T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42195602P 2002-10-29 2002-10-29
EP03781400A EP1558259B1 (en) 2002-10-29 2003-10-28 Urea derivatives as IL-8 receptor antagonists

Publications (1)

Publication Number Publication Date
CY1112135T1 true CY1112135T1 (el) 2015-11-04

Family

ID=32230293

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100624T CY1112135T1 (el) 2002-10-29 2011-06-29 Ανταγωνιστες υποδοχεα il-8

Country Status (16)

Country Link
US (2) US20060040952A1 (el)
EP (2) EP2388006A1 (el)
JP (1) JP4843220B2 (el)
AR (1) AR041834A1 (el)
AT (1) ATE504300T1 (el)
AU (1) AU2003287219A1 (el)
CY (1) CY1112135T1 (el)
DE (1) DE60336672D1 (el)
DK (1) DK1558259T3 (el)
ES (1) ES2362357T3 (el)
MY (1) MY143477A (el)
PE (1) PE20040607A1 (el)
PT (1) PT1558259E (el)
SI (1) SI1558259T1 (el)
TW (1) TW200418812A (el)
WO (1) WO2004039775A2 (el)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008517054A (ja) * 2004-10-20 2008-05-22 スミスクライン・ビーチャム・コーポレイション Ｉｌ−８受容体アンタゴニスト
US20090093451A1 (en) * 2006-04-21 2009-04-09 Smithkline Beecham Corporation IL-8 Receptor Antagonists
CN101495113A (zh) * 2006-04-21 2009-07-29 史密丝克莱恩比彻姆公司 Il-8受体拮抗剂
TW200817006A (en) * 2006-06-23 2008-04-16 Smithkline Beecham Corp IL-8 receptor antagonist
EP2203432A4 (en) * 2007-09-21 2011-04-27 Glaxosmithkline Llc PROCESSING METHOD
CA2956785A1 (en) * 2014-07-31 2016-02-04 Glaxosmithkline Intellectual Property Development Limited Use of cxcr2 antagonists for the prevention and/or treatment of chemotherapy induced peripheral neuropathy (cipn)
US11136315B2 (en) 2018-01-11 2021-10-05 Medshine Discovery Inc. CXCR2 antagonist
US20220340549A1 (en) * 2019-07-11 2022-10-27 Shenzhen Optimum Biological Technology Co., Ltd Crystalline form of cxcr2 antagonist and application thereof

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1792156A (en) 1928-01-17 1931-02-10 Gen Aniline Works Inc 5-halogen-2-amino-1-alkyloxy and 1-aralkyloxy-benzenes and intermediate products thereof and process of preparing them
US2363074A (en) 1938-06-16 1944-11-21 Geigy Ag J R Halogen substituted acylamino sulphonic acids of the aromatic series and their manufacture
US2407309A (en) 1942-02-04 1946-09-10 Squibb & Sons Inc Chemotherapeutic agents of the sulphonamide type
US2795610A (en) 1955-03-31 1957-06-11 Du Pont Hydroxy-phenyl alkyl ureas
BE639588A (el) 1962-11-06
US3996253A (en) 1966-01-11 1976-12-07 Minnesota Mining And Manufacturing Company Process for the preparation of color images
BE713279A (el) 1967-04-06 1968-08-16
CH506240A (de) 1969-02-04 1971-04-30 Ciba Geigy Ag Verwendung von N-Hydroxyphenyl-N'-phenylharnstoffen zur Bekämpfung schädlicher Mikroorganismen ausserhalb der Textilindustrie
SE370866B (el) 1968-03-21 1974-11-04 Ciba Geigy Ag
US3647819A (en) 1969-09-19 1972-03-07 Sterling Drug Inc Indazolylphenylureas and indazolyl-phenylthioureas
FR2100943A1 (en) 1970-07-23 1972-03-24 Ici Ltd O-carboylcarbanilides from anthranilic acid and substd - isocyanates - immuno-suppressive agents
US4048333A (en) 1971-08-23 1977-09-13 Medizinska Akademia Method for treating a picorna virus infection
DE2303761A1 (de) 1973-01-26 1974-08-01 Henkel & Cie Gmbh Neue n,n'-disubstituierte thioharnstoffe, deren herstellung sowie verwendung als antimikrobielle substanzen
US4008326A (en) 1973-12-26 1977-02-15 The Upjohn Company Substituted ureas and thioureas and pharmaceutical compositions thereof
US3932434A (en) 1974-08-30 1976-01-13 Eli Lilly And Company N-2-(6-hydroxybenzothiazolyl)-N'-phenyl (or substituted phenyl) ureas
JPS5598152A (en) 1979-01-16 1980-07-25 Hokko Chem Ind Co Ltd Phenylurea derivative
DE2928485A1 (de) 1979-07-14 1981-01-29 Bayer Ag Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen
GB2079480B (en) 1980-07-08 1984-05-16 Kodak Ltd Heat-activated photographic and thermal recording processes employing precursor compounds
US4608205A (en) 1983-03-09 1986-08-26 American Cyanamid Company Polyanionic benzene ureas
US4591604A (en) 1984-03-28 1986-05-27 American Cyanamid Company Method of inhibiting the complement system by administering multisulfonated naphthalene ureas
EP0344425B1 (en) 1988-03-30 1993-12-08 Warner-Lambert Company N-[[(2,6-disubstituted)phenyl]-N'- arylalkyl] ureas as antihypercholesterolemic and antiatherosclerotic agents
US5215570A (en) 1988-10-20 1993-06-01 Ciba-Geigy Corporation Sulfamoylphenylureas
US5290814A (en) 1988-11-21 1994-03-01 Burroughs Wellcome Co. Anti-atherosclerotic diaryl compounds
US5206234A (en) 1990-10-22 1993-04-27 Merck & Co., Inc. Benzolactam analogs as antagonists of cck
JPH05294935A (ja) 1991-03-15 1993-11-09 Green Cross Corp:The アミノピリジン系化合物
AU659861B2 (en) 1991-09-10 1995-06-01 Sansho Seiyaku Co., Ltd. Preparation for promoting hair growth
JP2558427B2 (ja) * 1992-06-08 1996-11-27 ゼネラル・エレクトリック・カンパニイ ポリカーボネート上にシリコーンを堆積する方法
NZ250916A (en) 1993-02-27 1995-08-28 Nihon Nohyaku Co Ltd N-heteroaryl-n'-phenylureas, their use as acat inhibitors
DK41193D0 (da) 1993-04-07 1993-04-07 Neurosearch As Ionkanalaabnere
US5312831A (en) 1993-05-12 1994-05-17 American Cyanamid Company Urethanes and ureas that induce cytokine production
CA2123728A1 (en) 1993-05-21 1994-11-22 Noriyoshi Sueda Urea derivatives and their use as acat inhibitors
US5547966A (en) 1993-10-07 1996-08-20 Bristol-Myers Squibb Company Aryl urea and related compounds
US5401758A (en) 1993-10-07 1995-03-28 Bristol-Myers Squibb Company Pyridinyl cyanoguanidine compounds
US5441984A (en) 1994-01-06 1995-08-15 Eli Lilly And Company Urea, thiourea and guanidine derivatives
US5576335A (en) 1994-02-01 1996-11-19 Nisshin Flour Milling Co., Ltd. Urea derivatives and their use as ACAT inhibitors
DE4413265A1 (de) 1994-04-16 1995-10-19 Basf Ag Hydroxyphenylharnstoffe
US5780483A (en) 1995-02-17 1998-07-14 Smithkline Beecham Corporation IL-8 receptor antagonists
EP0809492A4 (en) 1995-02-17 2007-01-24 Smithkline Beecham Corp IL-8 RECEPTOR ANTAGONISTS
US6005008A (en) 1996-02-16 1999-12-21 Smithkline Beecham Corporation IL-8 receptor antagonists
US6262113B1 (en) 1996-03-20 2001-07-17 Smithkline Beecham Corporation IL-8 receptor antagonists
US6211373B1 (en) * 1996-03-20 2001-04-03 Smithkline Beecham Corporation Phenyl urea antagonists of the IL-8 receptor
EP0912505A4 (en) 1996-06-27 2001-10-24 Smithkline Beecham Corp IL-8 RECEPTOR ANTAGONISTS
WO1997049287A1 (en) 1996-06-27 1997-12-31 Smithkline Beecham Corporation Il-8 receptor antagonists
WO1997049400A1 (en) 1996-06-27 1997-12-31 Smithkline Beecham Corporation Il-8 receptor antagonists
EP0907362A4 (en) 1996-06-27 1999-12-01 Smithkline Beecham Corp IL-8 RECEPTOR ANTAGONISTS
BR9709938A (pt) 1996-06-27 1999-08-10 Smithkline Beecham Corp Antagonistas dos receptores de il-8
EP0957907A4 (en) 1996-08-06 2001-08-16 Smithkline Beecham Corp IL-8 RECEPTOR ANTAGONISTS
WO1998005328A1 (en) 1996-08-06 1998-02-12 Smithkline Beecham Corporation Il-8 receptor antagonists
JP2000515554A (ja) 1996-08-06 2000-11-21 スミスクライン・ビーチャム・コーポレイション Ｉｌ―８受容体アンタゴニスト
AR008290A1 (es) 1996-08-15 1999-12-29 Smithkline Beecham Corp Nuevos compuestos que contienen guanidina utiles como antagonistas de los receptores de il-8, composiciones farmaceuticas que los contienenprocedimiento para la preparacion de dichos compuestos y procedimiento para la preparacion de intermediarios.
WO1998006398A1 (en) 1996-08-15 1998-02-19 Smithkline Beecham Corporation Il-8 receptor antagonists
US6335352B1 (en) 1996-08-15 2002-01-01 Smithkline Beecham Corporation IL-8 receptor antagonists
WO1998006262A1 (en) 1996-08-15 1998-02-19 Smithkline Beecham Corporation Il-8 receptor antagonists
EP0920417A4 (en) 1996-08-15 1999-12-29 Smithkline Beecham Corp IL-8 RECEPTOR ANTAGONISTS
US6214881B1 (en) 1996-08-21 2001-04-10 Smithkline Beecham Corporation IL-8 receptor antagonists
US5929250A (en) 1997-01-23 1999-07-27 Smithkline Beecham Corporation IL-8 receptor antagonists
HUP0001943A3 (en) 1997-01-23 2002-12-28 Smithkline Beecham Corp Benzimidazole and benzotriazole derivatives, their use, process for their preparation and pharmaceutical compositions containing them
US6436927B1 (en) 1997-02-12 2002-08-20 Smithkline Beecham Corporation IL-8 receptor antagonists
CA2294064A1 (en) 1997-07-29 1999-02-11 Smithkline Beecham Corporation Il-8 receptor antagonists
AR015426A1 (es) 1997-09-05 2001-05-02 Smithkline Beecham Corp Compuestos de benzotiazol antagonistas del receptor de il-8, composicion farmaceutica que los contiene, su uso para la manufactura de un medicamento,procedimiento para su preparacion, compuestos intermediarios y procedimiento para su preparacion
AR015425A1 (es) 1997-09-05 2001-05-02 Smithkline Beecham Corp Compuestos de benzotiazol, composicion farmaceutica que los contiene, su uso en la manufactura de un medicamento, procedimiento para su preparacion,compuestos intermediarios y procedimiento para su preparacion
JP2002509105A (ja) 1998-01-16 2002-03-26 スミスクライン・ビーチャム・コーポレイション Ｉｌ−８受容体アンタゴニスト
US6221889B1 (en) 1998-01-20 2001-04-24 Smithkline Beecham Corporation IL-8 receptor antagonists
WO2000006557A1 (en) 1998-07-27 2000-02-10 Smithkline Beecham Corporation Novel process for making il-8 receptor antagonists
CA2341711A1 (en) 1998-08-28 2000-03-09 Smithkline Beecham Corporation Process for making 2-amino-5-cyanophenol
WO2000012468A1 (en) 1998-08-28 2000-03-09 Smithkline Beecham Corporation An improved synthesis of 3-hydroxy-4-amino-benzonitrile
ATE240940T1 (de) 1998-09-23 2003-06-15 Tularik Inc Arylsulfonanilid-harnstoffe
UY25842A1 (es) * 1998-12-16 2001-04-30 Smithkline Beecham Corp Antagonistas de receptores de il-8
CO5170514A1 (es) 1999-05-28 2002-06-27 Smithkline Beecham Corp Antagonistas de los receptores de la il-8 nistas del receptor de la il-8
US20030225125A1 (en) 1999-06-16 2003-12-04 Smithkline Beecham Corporation IL-8 receptor antagonists
US6372933B1 (en) 1999-08-26 2002-04-16 Smithkline Beecham Corporation Process for preparing certain phenyl urea compounds
US6440993B1 (en) 1999-10-12 2002-08-27 Smithkline Beecham Corporation IL-8 receptor antagonists
EP1274413A4 (en) 2000-03-01 2005-08-10 Smithkline Beecham Corp IL-8 RECEPTOR ANTAGONISTS
MY133845A (en) 2000-03-10 2007-11-30 Smithkline Beecham Corp Il-8 receptor antagonists
JP2004504270A (ja) 2000-03-10 2004-02-12 スミスクライン・ビーチャム・コーポレイション Ｉｌ−８受容体アンタゴニスト
US6767922B2 (en) 2000-03-14 2004-07-27 Smithkline Beecham Corporation IL-8 receptor antagonists
US6664259B2 (en) 2000-03-16 2003-12-16 Smithkline Beecham Corporation Il-8 receptor antagonists
UY26627A1 (es) 2000-03-24 2001-09-28 Smithkline Beecham Corp Antagonistas de receptores de il-8
AU2001253172A1 (en) 2000-04-07 2001-10-23 Smith Kline Beecham Corporation Il-8 receptor antagonists
US6432960B2 (en) 2000-05-10 2002-08-13 Bristol-Myers Squibb Company Squarate derivatives of dihydropyridine NPY antagonists
JP2004509070A (ja) 2000-05-30 2004-03-25 スミスクライン・ビーチャム・コーポレイション Ｉｌ−８受容体アンタゴニスト
US20040132694A1 (en) 2001-01-16 2004-07-08 Palovich Michael R. Il-8 receptor antagonists
US20040048897A1 (en) 2001-01-16 2004-03-11 Mccleland Brent Il-8 receptor antagonists
CZ20032098A3 (cs) 2001-02-02 2004-01-14 Schering Corporation 3,4-Disubstituované cyklobuten-1,2-diony a farmaceutický prostředek
US20030204085A1 (en) 2001-02-02 2003-10-30 Taveras Arthur G. 3, 4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor antagonists
CZ20032639A3 (cs) 2001-03-30 2004-04-14 Smithkline Beecham Corporation Způsoby přípravy sloučenin obsahujících fenol
ATE338035T1 (de) 2001-06-05 2006-09-15 Boehringer Ingelheim Pharma 1,4-disubstituierte benzokondensierte cycloalkyl harnstoffverbindungen
US20040038854A1 (en) 2001-07-16 2004-02-26 Dillon Susan B. Use of il-8 receptor antagonists in the treatment of virus infections
US20030032802A1 (en) 2002-08-30 2003-02-13 Palovich Michael R. IL8-receptor antagonists
US20030028042A1 (en) 2002-08-30 2003-02-06 Palovich Michael R. Il8-receptor antagonists
US20030065170A1 (en) 2002-09-05 2003-04-03 Widdowson Katherine Louisa Il-8 receptor antagonists
EP1631559A4 (en) 2003-06-06 2008-08-27 Smithkline Beecham Corp IL-8 SB / SB RECEPTOR ANTAGONISTS
JP2008517054A (ja) 2004-10-20 2008-05-22 スミスクライン・ビーチャム・コーポレイション Ｉｌ−８受容体アンタゴニスト
US20090093451A1 (en) 2006-04-21 2009-04-09 Smithkline Beecham Corporation IL-8 Receptor Antagonists
TW200817006A (en) 2006-06-23 2008-04-16 Smithkline Beecham Corp IL-8 receptor antagonist

Also Published As

Publication number Publication date
DE60336672D1 (de) 2011-05-19
JP2006506404A (ja) 2006-02-23
TW200418812A (en) 2004-10-01
WO2004039775A2 (en) 2004-05-13
EP1558259A2 (en) 2005-08-03
MY143477A (en) 2011-05-31
EP1558259B1 (en) 2011-04-06
WO2004039775A3 (en) 2004-08-26
US20060040952A1 (en) 2006-02-23
ATE504300T1 (de) 2011-04-15
DK1558259T3 (da) 2011-07-11
ES2362357T3 (es) 2011-07-04
AU2003287219A8 (en) 2004-05-25
PE20040607A1 (es) 2004-09-18
US7709485B2 (en) 2010-05-04
AR041834A1 (es) 2005-06-01
AU2003287219A1 (en) 2004-05-25
JP4843220B2 (ja) 2011-12-21
EP2388006A1 (en) 2011-11-23
PT1558259E (pt) 2011-06-17
EP1558259A4 (en) 2009-04-08
SI1558259T1 (sl) 2011-06-30
US20090093492A1 (en) 2009-04-09

Similar Documents

Publication Publication Date Title
CY1112135T1 (el) Ανταγωνιστες υποδοχεα il-8
CY1113132T1 (el) Ανταγωνιστες υποδοχεα il-8
CY1106514T1 (el) Ανταγωνιστες υποδοχεων il-8
CY1108378T1 (el) 4-υποκατεστημενα παραγωγα 1-αμινοκυκλοεξανιου για την χρησιμοποιηση σαν προσδεματα υποδοχεα orl1 ή οπιακου υποδοχεα mu
CY1111317T1 (el) Παραγωγα 4-φαινυλοπυριδινης και χρηση αυτων ως ανταγωνιστων υποδοχεων της νκ-1
CY1112628T1 (el) Νεοι αναστολεις κινασης
EA200300528A1 (ru) 1-арил-или 1-алкилсульфонилгетероциклилбензазолы в качестве лигандов 5-гидрокситриптамина-6
CY1113413T1 (el) Συνθεση και αντι-ιικη δραστηριοτητα των υποκατεστημενων παραγωγων αζαϊνδολοοξοοξικης πιπεραζινης
CY1105994T1 (el) Aναδιαταγμενες πεντανολες, μεθοδος για την παραγωγη αυτων και η χρηση αυτων ως αντιφλεγμονωδων
CY1110669T1 (el) Χρησιμοποιηση βενζο-συγχωνευμενων ετεροκυκλικων παραγωγων σουλφαμιδιου για τη θεραπευτικη αγωγη της καταθλιψης
CY1110362T1 (el) Ν-(2-αρυλαιθυλο)βενζυλαμινες ως ανταγωνιστες του 5-ητ6 υποδοχεα
CY1105253T1 (el) Ετepοπολυκυκλικες ενωσεις και η χρησιμοποιηση τους ως ανταγωνιστες μεταβολοτροπου γλουταμινικου υποδοχεως
CY1109908T1 (el) 3,4-δι υποκατεστημενες κυκλοβουτενο-1,2-διονες σαν συνδετηρες υποδοχεα cxc-χημειοκινης
CY1110977T1 (el) Υποκατεστημενα παραγωγα ινδολης για φαρμακευτικη συνθεση για θεραπεια ασθενειων του αναπνευστικου
PA8571001A1 (es) 2-(2,6-diclorofenil)-diarilimidazoles
CY1106509T1 (el) Αμιδοακετονιτριλια κατα των παρασιτων του εντερου
EA200601007A1 (ru) 7-фенилалкилзамещённые 2-хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(адф-рибоза)полимеразы
CY1107985T1 (el) Ccr1 ανταγωνιστες για την αγωγη μεταξυ αλλων απομυελινωτικης φλεγμονωδους νοσου
CY1105734T1 (el) Nεα προ-φαρμακα του 1-μεθυλο-2-(4-αμιδινοφαινυλαμινομεθυλο)-βενζιμιδαζολ-5-υλιο-καρβοξυλικο οξυ-(ν-2-πυριδυλο-ν-2-υδροξυκαρβονυλαιθυλο)-αμιδιου, η παρασκευη και η χρησιμοποιηση τους ως φαρμακων
CY1106526T1 (el) Παραγωγα ν-θειαζολ-2-υλο-βενζαμιδης
ATE347555T1 (de) 6-aminomorphinanderivate, herstellungsverfahren dafür und deren verwendung
EA200602281A1 (ru) Гетероарилсульфоны и сульфонамиды и их терапевтические применения
BRPI0417858A (pt) composto, composição farmacêutica, e, uso de uma composição farmacêutica
CY1119257T1 (el) Θεραπεια του νευροπαθητικου πονου με ανταγωνιστες υποδοχεα δεξτρομεθορφανης n-meθυλ-d-ασπαρτικων (nmda)
ATE498600T1 (de) Inden derivate als pharmazeutika